RALEIGH, N.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced a collaboration with Hims & Hers™, one of the largest digital health platforms for men, to make KYZATREX®, an FDA-approved oral testosterone replacement therapy for adult men with low or no testosterone levels due to certain medical conditions, available to patients through the Hims & Hers platform in the coming months. This marks the first time Hims & Hers will offer an FDA-approved oral testosterone therapy, und ...

So, uh, first I'm going to talk about why men's hormonal health is in crisis. And I'm going to frame it in a way where we're really talking about health. Um, I'm going to specifically talk about testosterone, but not testosterone from a like I I want to be big and strong.Testosterone from the perspective of living a long and healthy life and, uh, avoiding chronic disease. So, uh, two really important points. The two greatest drivers of long life seen in published peer-reviewed research are high levels of st ...

Company Overview - Lipocine Inc. is a biopharmaceutical company focused on effective oral delivery of therapeutics, leveraging its proprietary technology platform [7] - TLANDO is a testosterone replacement therapy approved by the US FDA for adult males with testosterone deficiency, developed using Lipocine's Lip'ral drug delivery technology [4][8] Partnership and Market Opportunity - Lipocine has entered into a license and supply agreement with Aché Laboratórios Farmacêuticos S.A, granting exclusive rights to market TLANDO in Brazil [1][3] - The Brazilian market for prescription testosterone products is substantial, with a compound annual growth rate (CAGR) of 34% from 2019 to 2023, and currently no oral testosterone therapy registered in Brazil [2] Aché's Profile - Aché is a leading Brazilian pharmaceutical company with nearly 60 years of experience, focusing on improving lives through a diverse portfolio that includes prescription medications, generics, and OTC products [5][6] - Aché has over 350 brands and 900 drug presentations across more than 150 therapeutic categories, reaching over 20 countries [6] Financial Terms of the Agreement - Under the agreement, Lipocine received an upfront payment and is eligible for additional payments upon achieving regulatory milestones, as well as royalties on net sales [3] - Aché will handle the regulatory submission and approval process in Brazil, leveraging its established commercial capabilities and regulatory expertise [3]